WATERTOWN, Mass.--(BUSINESS WIRE)--June 12, 2006--Panacos Pharmaceuticals, Inc. (Nasdaq:PANC - News), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced the initiation of a Phase 2b clinical trial of bevirimat (previously designated PA-457), the Company's lead drug candidate for the treatment of HIV. Institutional Review Board (IRB) and other approvals have been received at initial study sites and the study is now open for enrollment.
